SCYNEXIS (SCYX) Expected to Announce Earnings on Wednesday

SCYNEXIS (NASDAQ:SCYX) will likely be issuing its Q4 2025 results before the market opens on Wednesday, March 11th. Analysts expect the company to announce earnings of $0.29 per share and revenue of $8.10 million for the quarter. Interested persons may review the information on the company’s upcoming Q4 2025 earning report for the latest details on the call scheduled for Thursday, March 12, 2026 at 9:30 AM ET.

SCYNEXIS Trading Up 0.3%

Shares of SCYX stock opened at $0.75 on Wednesday. The firm’s fifty day moving average price is $0.71 and its two-hundred day moving average price is $0.75. SCYNEXIS has a 1 year low of $0.57 and a 1 year high of $1.31. The firm has a market capitalization of $31.55 million, a P/E ratio of -1.47 and a beta of 1.33.

Institutional Trading of SCYNEXIS

A number of large investors have recently added to or reduced their stakes in SCYX. Jane Street Group LLC acquired a new position in shares of SCYNEXIS during the 2nd quarter worth about $27,000. Bridgeway Capital Management LLC lifted its stake in SCYNEXIS by 4.2% in the 2nd quarter. Bridgeway Capital Management LLC now owns 368,180 shares of the company’s stock valued at $248,000 after purchasing an additional 14,689 shares during the last quarter. Geode Capital Management LLC grew its holdings in SCYNEXIS by 7.1% during the fourth quarter. Geode Capital Management LLC now owns 449,223 shares of the company’s stock worth $284,000 after purchasing an additional 29,775 shares during the period. Vanguard Group Inc. increased its position in SCYNEXIS by 6.4% during the third quarter. Vanguard Group Inc. now owns 1,762,322 shares of the company’s stock worth $1,357,000 after buying an additional 105,600 shares during the last quarter. Finally, Goldman Sachs Group Inc. bought a new stake in SCYNEXIS in the fourth quarter valued at approximately $1,255,000. Institutional investors and hedge funds own 54.37% of the company’s stock.

Analysts Set New Price Targets

Separately, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of SCYNEXIS in a research report on Monday, December 29th. One research analyst has rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Hold” and an average target price of $3.00.

SCYNEXIS Company Profile

SCYNEXIS, Inc is a late‐stage biopharmaceutical company focused on developing and commercializing novel anti‐infective therapies. Headquartered in Jersey City, New Jersey, the company’s primary research and development efforts center on combating invasive and chronic fungal infections, an area of high unmet medical need. SCYNEXIS’s scientific platform is built around its proprietary triterpenoid class of antifungals, which are designed to address resistance and safety limitations associated with existing treatments.

The company’s lead product candidate, ibrexafungerp, represents the first oral glucan synthase inhibitor to reach clinical development.